Background: The purpose of the study was to evaluate the effects of erlotinib on epidermal
growth factor receptor (EGFR)-related signaling elements in tumor and skin from patients …

Purpose Pharmacodynamic tissue studies were conducted on a phase I/II trial of erlotinib
and cisplatin in patients with recurrent or metastatic head and neck squamous cell …

Background The purpose of this study was to determine if there are differences in biomarker
modulation and epidermal growth factor receptor (EGFR) degradation between the tumor …

Purpose This phase I study determined the maximal-tolerated dose, dose-limiting toxicities,
pharmacokinetics, and recommended dose of erlotinib with docetaxel. Patients and methods …

Pharmacokinetic and pharmacodynamic studies have an important role in the optimization
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …

Purpose To determine the efficacy and safety profiles of erlotinib in patients with advanced
recurrent and/or metastatic squamous cell cancer of the head and neck (HNSCC). Patients …

A clinical study was conducted to determine the safety and efficacy of neoadjuvant erlotinib
treatment in patients with head and neck squamous cell carcinoma [Thomas F, Rochaix P …

Objective The objective of this study is to examine the efficacy of erlotinib and gefitinib with
respect to epidermal growth factor (EGF) and cetuximab response in head and neck cancer …

Purpose To evaluate changes in epidermal growth factor receptor (EGFR) phosphorylation
and its downstream signaling in tumor and surrogate tissue biopsies in patients with …

Aim The aim of this study was to investigate if biomarkers of individual drug metabolism,
respectively, the erlotinib/O-desmethyl-erlotinib metabolic ratio, may be a predictive factor for …